On Vaccines and Vaccinology, in COVID and Beyond
The a16z Show14 Aug 2020

On Vaccines and Vaccinology, in COVID and Beyond

WHEN are we going to have a COVID-19 vaccine, and how the heck are we going from (what’s been traditionally been up to) 12 years or so of vaccine development compressed into 12 months or so? What will and won’t be compromised here, and where do new technologies -- like mRNA or messenger RNA vaccines -- come in? Where will vaccines likely be distributed first, who will and won't get them initially, both across populations... and nations?

Rajeev Venkayya, president of the Global Vaccine Business Unit at Takeda Pharmaceutical Company and former White House Special Assistant to the President for Biodefense (where, among other things, he was the principal author of the National Strategy for Pandemic Influenza) joins this special deep-dive episode of the a16z Podcast, in conversation with general partner Jorge Conde to discuss all things vaccines. Including where does manufacturing and scale-up come in -- is "plug and play" really here? -- and by the way, why have we traditionally used eggs in growing vaccines?

Where and how can startups and others participate in vaccine development, given how competitive, time-consuming, capital intensive, and risky it is to develop (and sell) them? Can we decouple the question of how we reopen schools with when we have a vaccine? And how do we maintain not just safety and efficacy of vaccines but trust and transparency when it comes to mis/information? We may actually see the emergence of a "Neo Anti-Vaxxer" thanks to the rush... but we may also be entering a renaissance for vaccinology after this pandemic. So what changes, what doesn't?

image: Jernej Furman / Flickr

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episoder(1000)

The New Space Race: NASA, Artemis, and the Race to the Moon

The New Space Race: NASA, Artemis, and the Race to the Moon

Morgan Brennan speaks with NASA Administrator Jared Isaacman about the next phase of American space exploration and the urgency behind returning to the moon. They discuss the Artemis program, the chal...

6 Mai 29min

Building Blackstone, Backing Costco, with Tony James

Building Blackstone, Backing Costco, with Tony James

David Haber speaks with Tony James about building enduring firms across multiple eras of finance. From joining DLJ when it was a subscale firm to helping grow Blackstone into one of the largest asset ...

5 Mai 1h 23min

Sarah Rogers: Free Speech, AI Diplomacy, and What America Owes Its Allies

Sarah Rogers: Free Speech, AI Diplomacy, and What America Owes Its Allies

Katherine Boyle speaks with Sarah Rogers, Under Secretary for Public Diplomacy, about the intersection of AI, free speech, and global information systems. They discuss how major technological shifts, ...

4 Mai 24min

Balaji and Taylor Lorenz on AI and Media

Balaji and Taylor Lorenz on AI and Media

Theo Jaffee speaks with Balaji Srinivasan and Taylor Lorenz about how AI is reshaping media, trust, and online communication. Building on prior public disagreements between the two, the conversation r...

1 Mai 51min

Workday’s Last Workday? AI and the Future of Enterprise Software

Workday’s Last Workday? AI and the Future of Enterprise Software

Elena Burger speaks with Joe Schmidt, partner on the enterprise team at a16z, about the future of enterprise software in the age of AI. Using Workday as a case study, they discuss why many of today’s ...

30 Apr 29min

The Shift in Global Drug Development

The Shift in Global Drug Development

Theo Jaffee and Gabriel Dickinson speak with Cremieux about China’s rapid rise to the top of global clinical trial output. They discuss the regulatory reforms that accelerated China’s progress, the su...

29 Apr 57min

John and Patrick Collison on Stripe's Growth, Agent Commerce, and the Future of Software

John and Patrick Collison on Stripe's Growth, Agent Commerce, and the Future of Software

This interview with Stripe cofounders John and Patrick Collison originally aired on TBPN. They discuss Stripe's 34% growth and new employee tender offer, how agent commerce and stablecoins may require...

28 Apr 20min

Ben Horowitz on Venture Capital and AI

Ben Horowitz on Venture Capital and AI

Anjney Midha, founder of AMP PBC, speaks with Ben Horowitz, cofounder of a16z, about how venture capital changed from a small, relationship-driven business into a scalable system for backing new techn...

27 Apr 1h 9min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
rss-penger-polser-og-politikk
e24-podden
rss-pa-konto
rss-borsmorgen-okonominyhetene
rss-skravla-gar
pengepodden-2
finansredaksjonen
pengesnakk
utbytte
morgenkaffen-med-finansavisen
rss-sunn-okonomi
lederpodden
stormkast-med-valebrokk-stordalen
okonomiamatorene
rss-politisk-preik
liberal-halvtime
livet-pa-veien-med-jan-erik-larssen